Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering
Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering
复制标题
DOI：
10.1160/th05-04-0245
复制
发表时间：
2005-11-01
影响因子：
6.7
通讯作者：
Badimon, L
中科院分区：
文献类型：
--
作者：
Casani, L;Sanchez-Gomez, S;Badimon, L
3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂广泛用于心血管疾病的管理和预防。除了其主要活性，降低血脂，他汀类药物已显示出广泛的其他作用，可能有助于他们在预防心血管疾病的好处。我们的目的是研究是否用他汀类药物普伐他汀治疗可以减少由受损血管引发的血栓形成而不改变血浆胆固醇水平。通过以高胆固醇血症（HL）饮食喂养猪100天来开发胆固醇钳夹动物模型;在最后50天中，将它们随机分配接受安慰剂（HLC）或普伐他汀（5 mg . kg（-1）。第（-1）天）（HLP）。同时研究了正常胆固醇血症对照组（NLC）。两组之间的总胆固醇、LDL和HDL血浆水平无显著差异;然而，普伐他汀显著抑制由侵蚀和破坏的血管壁触发的附壁血栓形成（P
Inhibitors of 3-hydroxy-3-methylglutaryl coenzymeA reductase are widely used in the management and prevention of cardiovascular disease. In addition to its major activity, plasma lipid lowering, statins have shown a wide spectrum of additional effects that may contribute to their benefits in the prevention of cardiovascular disease. Our objective was to study whether treatment with a statin, pravastatin, could reduce thrombosis triggered by damaged vessels without changing plasma cholesterol levels. A cholesterol-clamp animal model was developed by feeding swine for 100 days on an hypercholesterolemic (HL) diet; in the last 50 days, they were randomly assigned to receive either placebo (HLC) or pravastatin (5 mg . kg(-1). day(-1)) (HLP) in addition to the hypercholesterolemic diet. A normocholesterolemic control group (NLC) was simultaneously studied. There were no significant differences in total cholesterol, LDL and HDL plasma levels between the two groups; however, mural thrombosis triggered by both an eroded and disrupted vessel wall was significantly inhibited by pravastatin (P